{"id":"NCT00834080","sponsor":"Alkermes, Inc.","briefTitle":"ALK21-021: A Safety Study of Medisorb速 Naltrexone (VIVITROL速) Administered to Health Care Professionals","officialTitle":"Open-Label Study of the Safety and Tolerability of VIVITROL Administered to Health Care Professionals Participating in an Extended Outpatient Treatment Program for Opioid Dependence","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-03","primaryCompletion":"2012-05","completion":"2012-05","firstPosted":"2009-02-03","resultsPosted":"2013-07-29","lastUpdate":"2018-12-11"},"enrollment":38,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Opiate Dependence"],"interventions":[{"type":"DRUG","name":"Medisorb naltrexone 380 mg","otherNames":["VIVITROL 380 mg","Naltrexone for extended-release injectable suspension"]}],"arms":[{"label":"Medisorb naltrexone 380 mg (VIVITROL)","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine the safety and tolerability of Medisorb速 naltrexone (VIVITROL速) when administered over a period of 24 months to health care professionals who have a history of opioid dependence.","primaryOutcome":{"measure":"Number of Subjects Reporting at Least 1 Treatment-emergent Adverse Event (TEAE) While on Study.","timeFrame":"2 years (Baseline to end of study)","effectByArm":[{"arm":"VIVITROL","deltaMin":37,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":7},"locations":{"siteCount":11,"countries":["United States"]},"refs":{"pmids":["28358754"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":38},"commonTop":["Nausea","Injection site pain","Anxiety","Headache","Upper respiratory tract infection"]}}